软脑膜癌病 (LC) 是乳腺癌的一种转移性并发症，给受影响的患者带来非常差的预后和令人痛苦的神经系统症状。虽然随着癌症患者生存率的提高，LC 的发病率有所上升，但目前还没有既定的 LC 治疗方案，并且比较现有疗法的临床试验数据有限。在这里，对 pubmed 和 Cochrane 数据库进行了全面的文献检索。总结了乳腺癌 LC 的当前治疗方式及其安全性/疗效概况。讨论了新兴疗法在 LC 中的作用，包括靶向药物、CAR-T、免疫检查点抑制剂、CDK 抑制剂和新型抗体偶联物。还提出了一种 LC 治疗途径，以指导临床医生治疗这种严重的乳腺癌转移并发症。版权所有 © 2024 Elsevier B.V. 保留所有权利。

Leptomeningeal carcinomatosis (LC) is a metastatic complication of breast cancer that imparts a very poor prognosis and distressing neurologic symptoms in affected patients. While the incidence of LC has risen with improving survival rates for cancer patients, there remains no established treatment protocol for LC and clinical trial data comparing available therapies is limited. Here, a comprehensive literature search of the pubmed and Cochrane databases was performed. Current treatment modalities and their safety/ efficacy profiles are summarized for LC in breast cancer. Roles for emerging therapies in LC are discussed, including targeted agents, CAR-T, immune checkpoint inhibitors, CDK inhibitors and novel antibody conjugates. A treatment pathway for LC is also proposed to guide clinicians through management of this severe metastatic complication of breast cancer.Copyright © 2024 Elsevier B.V. All rights reserved.